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Abstract
Background: Human resources are a major cost driver in childhood pneumonia case management. Introduction of
13-valent pneumococcal conjugate vaccine (PCV-13) in Malawi can lead to savings on staff time and salaries due to
reductions in pneumonia cases requiring admission. Reliable estimates of human resource costs are vital for use in
economic evaluations of PCV-13 introduction.
Methods: Twenty-eight severe and twenty-four very severe pneumonia inpatients under the age of five were
tracked from admission to discharge by paediatric ward staff using self-administered timesheets at Mchinji District
Hospital between June and August 2012. All activities performed and the time spent on each activity were
recorded. A monetary value was assigned to the time by allocating a corresponding percentage of the health
workers’ salary. All costs are reported in 2012 US$.
Results: A total of 1,017 entries, grouped according to 22 different activity labels, were recorded during the
observation period. On average, 99 min (standard deviation, SD = 46) were spent on each admission: 93 (SD = 38)
for severe and 106 (SD = 55) for very severe cases. Approximately 40 % of activities involved monitoring and
stabilization, including administering non-drug therapies such as oxygen. A further 35 % of the time was spent on
injecting antibiotics. Nurses provided 60 % of the total time spent on pneumonia admissions, clinicians 25 % and
support staff 15 %. Human resource costs were approximately US$ 2 per bed-day and, on average, US$ 29.5 per
severe pneumonia admission and US$ 37.7 per very severe admission.
Conclusions: Self-reporting was successfully used in this context to generate reliable estimates of human resource
time and costs of childhood pneumonia treatment. Assuming vaccine efficacy of 41 % and 90 % coverage, PCV-13
introduction in Malawi can save over US$ 2 million per year in staff costs alone.
Keywords: Time use, Pneumonia, Provider costs, Pneumococcal conjugate vaccine, PCV-13, Children, Malawi
* Correspondence: fiammetta.bozzani@lshtm.ac.uk
1Department of Global Health and Development, London School of Hygiene
& Tropical Medicine, 15-17 Tavistock Place, London WC1H 9SH, UK
2Institute for Global Health, University College London, London, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bozzani et al. BMC Health Services Research  (2016) 16:314 
DOI 10.1186/s12913-016-1573-5
Background
Pneumonia is the leading cause of mortality in children
under 5 years of age worldwide, causing an estimated 1.3
million deaths in 2011 [1]. The largest burden of
morbidity and mortality is borne by the world’s poorest
countries, with about half of all pneumonia deaths occur-
ring in the African region [1]. In Malawi, a 13-valent
pneumococcal conjugate vaccine (PCV-13) against Strepto-
coccus pneumoniae, the pathogen responsible for the
largest proportion of pneumonia cases, was introduced in
2011 with support from the GAVI Alliance.
The pace of new vaccine adoption has been accelerat-
ing in recent years, with more sophisticated and expen-
sive products becoming increasingly available on the
market [2]. This can put a strain on the Expanded
Programme on Immunization (EPI), the World Health
Organization’s (WHO) initiative aimed at securing
access to vaccination for all children in developing coun-
tries. In order to achieve the Global Immunization
Vision and Strategy advocated by the WHO and the
United Nations Children’s Fund (UNICEF), the 72 poor-
est countries in the world will have increased their an-
nual immunisation spending from approximately US$
2.5 billion in 2005 to US$ 4 billion between 2006 and
2015 [3]. Since co-payments on vaccines and injection
supplies procured are required from all countries seek-
ing GAVI Alliance support to introduce a new vaccine
[4], information on the cost-effectiveness of any addi-
tions to the EPI in low-income settings such as Malawi
are vital for both the national Government, in deciding
on uptake, and GAVI, in deciding whether to offer sup-
port. To inform these decisions, cost-effectiveness
models compare the costs of introducing a vaccine with
the cost of treating childhood pneumonia given the pre-
and post-introduction incidence rates [5].
While the human resource (HR) costs of delivering a
dose of vaccination have been previously estimated in a
variety of high- and low-income settings [6–8], no stud-
ies to date have provided reliable and comprehensive
treatment cost estimates in low-income countries that
differentiate between in- and out-patient care, separate
health provider and patient costs, and list the relative
contributions of different cost components including HR
[9–12]. The existing estimates of time spent by health
care workers on specific conditions other than childhood
pneumonia in sub-Saharan Africa suggest that there are
substantial efficiency gains to be made by increasing
their productivity [13, 14], and that the share of human
resources costs represents approximately one third of
total bed-day costs [15]. Reporting these estimates is
particularly relevant given the ongoing human resource
crisis in many parts of sub-Saharan Africa, including
Malawi [16]. Treatment cost estimates for vaccine-
preventable childhood illnesses are more prevalent in
Latin America, although among the cost of illness stud-
ies included in a recent systematic review [17], only one
reports the share of human resources costs, which was
approximately 22 % of total under-5 pneumonia treat-
ment costs [18].
Literature on the definitions and applications of existing
methodologies for measuring and valuing the time of hu-
man resources for health is scarce and dated [19]. The ‘gold
standard’ for this purpose is the time and motion tech-
nique, which has mostly been employed to analyse three
sets of problems: adoption of new technologies, health
workers productivity and tracking workload [20–22]. Other
techniques in the literature include self-administered time-
sheets and patient interviews [19]. Data from time and
motion studies are considered of better quality because of
the use of external observers, who objectively record, label
and time with a stopwatch all activities carried out by
health facility staff throughout the working day. However,
self-administered questionnaires were found to be in good
agreement with time and motion results when measuring
contact time with patients, as opposed to non-productive
time [19], and were identified as a viable low-cost alterna-
tive to time and motion studies [23].
The objective of this study is to estimate the time spent
by ward staff on case management activities for inpatients
under the age of 5 diagnosed with severe and very severe
pneumonia. We also aim to assign a monetary value to
the health workers’ time, in order to produce an estimate
of HR costs per childhood pneumonia admission and of
the annual costs of childhood pneumonia both at the facil-
ity and at the national level. These results, together with
existing estimates of the costs of delivering a dose of
vaccine, can be used in economic evaluation to model the
potential time and monetary savings resulting from the
introduction of PCV-13 in Malawi. While the introduction
is likely to have a positive cost in terms of staff time for
training and vaccine administration, effective vaccination
may reduce the severity of pneumonia episodes and,
therefore, the number of pneumonia cases requiring ad-
mission. Moreover, reduced severity can lead to shorter
hospital stays for those children who are admitted. In
order to estimate the duration and costs of ward staff care,
we collected time use data using self-administered time-
sheets alongside an ongoing full economic evaluation of
PCV-13 introduction in Malawi (McCollum ED, Nambiar,
B, et al. Impact of the 13-valent pneumococcal conjugate
vaccine on clinical and hypoxemic childhood pneumonia
at the community, health centre and hospital levels over
three years in Malawi: a time series analysis of two dis-
tricts, under review). The innovative use of this method in
Malawi also enables us to reflect on the viability and use-
fulness of applying this method in a low-income context
for calculating HR costs to be used in decision analytic
modeling.
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Methods
Data collection
Data was collected between June and August 2012 at
Mchinji District Hospital, a secondary-level government
facility in rural Malawi. We aimed to recruit a sample of
30 severe and 30 very severe pneumonia inpatients
under the age of five from the paediatric ward after
obtaining informed consent from their guardians. Pneu-
monia severity was classified according to the WHO
guidelines based on clinical signs adapted for Malawi
and following oxygen saturation thresholds for hypoxae-
mic pneumonia (normal: 96–100 %; severe: 90 < 95 %
saturation; very severe: <90 % saturation) [24, 25]. The
children were then tracked from admission to discharge
by the ward personnel who attended to them. The
personnel were asked to record all activities carried out
on or for the patient and the time spent on the patient
during each day of hospital stay. Elapsed time was mea-
sured using a wall clock and rounded to the closest mi-
nute. Only the time spent by clinical and support staff
directly involved in care provision was measured. The
time of overhead staff outside the admission ward that
did not have direct contact with the children (i.e. kit-
chen, laundry, security, administration, maintenance and
cleaning services staff ) was not included.
Ward staff were trained to fill in the study forms and
spot checks were performed by three study clinicians
based at the facility on a daily basis to avoid over-reporting
of the time spent with patients. To further reduce report-
ing bias, during training it was emphasized that the study
forms were not collected for the purpose of appraising per-
formance. In addition to regular oversight, spot checks
were conducted by two external supervisors to monitor
data quality and the handling of questionnaires, as well as
to troubleshoot any issues arising during implementation.
The data collection forms were structured as logbooks, as
this was found to be the easiest format for facility staff to
follow. One form was filled for each patient, where all ac-
tivities and their duration on each day of admission were
recorded. On each form, ward staff were also asked to rec-
ord the admission and discharge dates, diagnosis and
pneumonia severity as well as staff cadres. The complete
list of activities and health worker cadres included in the
study is shown in Table 1. An average of 8 h per shift and
5 shifts per week was used in the analysis, which corre-
sponds to the official policy in Malawi. This was agreed
upon in consultation with clinical staff as a reasonable
average, taking into account both overtime and absences.
A monetary value was then assigned to the time spent
on each patient by allocating a corresponding percentage
of the health workers’ monthly salary. The official salary
scales for all clinical and support staff were obtained
from the Ministry of Health and median salaries for each
cadre, which assumed a seniority level corresponding to
3.5 years of experience, were used in the calculations. All
costs are presented in 2012 US$.
To move from the time spent on index or sample pa-
tients to an estimate of time spent treating all pneumonia
cases presenting at health facilities in Malawi, we first
multiplied the cost estimates by the number of patients
with severe and very severe pneumonia admitted during 1
year. We then multiplied the annual human resource cost
at the hospital by the annual rate of pneumonia cases in
children under the age of five presenting at health facilities
in the country. The time horizon of 1 year was selected as
it is the most common budgeting period for health facil-
ities. The total number of inpatients admitted to Mchinji
District Hospital during 2012 was obtained from hospital
Table 1 Description of activities and staff involved in the
management of under-5 pneumonia inpatients
Activities Personnel N
Assessment, monitoring
and stabilisinga
Senior clinical cadres
OPD assessment/admission Nursing officer 1
Monitoring oxygen saturation Senior clinical technician 1
Oxygen therapy Other clinical cadres
Monitoring vital signs Clinical technician 4
Intravenous fluid infusion Nurse technician 12
Oral rehydration Medical assistant 8
Administering injections Auxiliary nurse 1
Benzylpenicillin Health surveillance
assistant
1
Chloramphenicol Support staff
Ceftriaxone Hospital attendant 1
Gentamicin Ward clerk 1
Administering other drugs
Paracetamol
Cotrimoxazole
Salbutamol
Aminophylline
Quinine
Artemisinin-based
combination therapy
Diagnostic tests
HIV antibody test
Malaria blood film
Administrative tasks
Ward round
Discharge paperwork
Other paperwork
Setting review appointment
a during the study period, no x-ray facilities were available at Mchinji
District Hospital
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surveillance data collected as part of the PCV-13 effective-
ness trial taking place alongside the economic evaluation
(McCollum ED, Nambiar, B, et al. Impact of the 13-valent
pneumococcal conjugate vaccine on clinical and hypox-
emic childhood pneumonia at the community, health
centre and hospital levels over three years in Malawi: a
time series analysis of two districts, under review). Esti-
mates of the number of children under the age of five and
of pneumonia incidence rates in this age group were ob-
tained from the Comprehensive Multi-Year Plan (cMYP)
submitted to the GAVI Alliance for the periods 2010–
2014 and 2012–2016 [26, 27].
The study received ethics approval from the National
Health Sciences Research Committee in Malawi (proto-
col 941) and from the University College London (UCL)
Research Ethics Committee (protocol 2006/002).
Data analysis
The data were analysed in Stata, Version 12. The mean
and standard deviation of the minutes spent on different
activities were calculated and stratified by pneumonia
severity. When more than one activity was recorded in
one time slot by the same individual staff member, a
weight was applied to each activity based on its average
duration when performed on its own. For example,
when a member of staff reported monitoring vital signs
during a ward round, the time assigned to monitoring
vital signs was equal to the average duration of the activity
when performed individually.
Differences in the duration of activities between severe
and very severe cases were analysed by t-tests using indi-
vidual activities rather than patients as the unit of analysis,
to investigate whether the same activity took longer when
performed for very severe than for severe cases.
After assigning a monetary value to the time spent on
pneumonia admissions, the net time costs at population
level were modeled using estimates of vaccine efficacy
and pneumonia prevalence. Sensitivity analysis was
performed by varying estimates of the reduction in the
incidence of severe pneumonia after PCV-13 introduc-
tion. The vaccine efficacy estimates for PCV-13 of 65 %
(range: 22–100 %) against all-cause very severe pneumo-
nia and 0 % against all-cause severe pneumonia were
based on the results of the PCV-13 effectiveness trial
(McCollum ED, Nambiar, B, et al. Impact of the 13-
valent pneumococcal conjugate vaccine on clinical and
hypoxemic childhood pneumonia at the community,
health centre and hospital levels over three years in
Malawi: a time series analysis of two districts, under re-
view). Vaccine coverage 3 years post-introduction was
75 % (McCollum ED, Nambiar, B, et al. Impact of the
13-valent pneumococcal conjugate vaccine on clinical
and hypoxemic childhood pneumonia at the community,
health centre and hospital levels over three years in
Malawi: a time series analysis of two districts, under re-
view). A positive and negative variation of 25 % in the
annual number of pneumonia admissions under the age
of five at Mchinji District Hospital was also considered
in the sensitivity analysis.
Results
Data were collected for 28 severe and 24 very severe
pneumonia cases under the age of five. The caregivers of
five children, one with severe and four with very severe
pneumonia, refused to take part in the study. The target
number of participants, 30 for each diagnosis, was not
achieved due to a lower than expected number of cases
presenting at the facility during the recruitment period.
Nineteen participants were female and 33 were male.
Mean age was 15 months, with 75 % of the children
aged below 2 years. The average duration of hospital ad-
mission was 4 days for children with severe pneumonia
(SD = 1.02) and 5 days for very severe cases (SD = 1.79).
A total of 1017 entries, grouped according to 22 differ-
ent activity labels, were recorded during the observation
period. On average, 99 min (SD = 46) were spent on care
and case management activities for each admission:
93 min (SD = 38) for severe and 106 min (SD = 55) for
very severe cases. Figure 1 shows the distribution of re-
corded activities by type: approximately 36 % of activities
involved monitoring and stabilization of the child’s con-
dition, including administration of non-drug therapies
such as oxygen, oral rehydration and intravenous fluids,
and a further 34 % of the time was spent on injecting
antibiotics.
The average duration of individual activities per ad-
mission according to pneumonia severity is presented in
Table 2. The most time-consuming activity for both
severe and very severe cases was administering antibi-
otics by injection, which was performed an average of 3
times per day for each child. The mean time per admis-
sion for injecting benzylpenicillin, including prepar-
ation time, was 24 min for severe pneumonia cases
Fig. 1 Description of reported activities by type (n = 1071)
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(SD = 17 min) and 4 min for very severe cases (SD =
7 min), while injecting chloramphenicol took on aver-
age 2 min among severe cases (SD = 5 min) and 22 min
(SD = 14 min) among very severe. No strong evidence
of any single task lasting significantly longer for more
or less severe patients was found except for oxygen
therapy, which was administered to 5 out of 28, and 20
out of 24 children with severe and very severe pneumo-
nia, respectively (p = 0.001, Table 2). While most activ-
ities were performed for both severe and very severe
cases, antimalarials were administered to one in five
severe cases and never to very severe cases, suggesting less
uncertainty in the diagnosis of very severe pneumonia
even in the absence of a functioning x-ray machine.
Staff time
Nurses supplied 60 % of the total time spent on pneumo-
nia admissions, other clinicians 25 % and support staff
15 %. Table 3 summarises the time per patient spent by se-
nior, specialised and support personnel with severe and
very severe cases. While there is no evidence of a signifi-
cant difference in the amount of time provided by senior
clinical staff and nurses between severe and very severe
cases, support staff such as hospital attendants and ward
Table 2 Time spent on individual activities for severe (n = 28) and very severe inpatients (n = 24)
Severe Very severe
N Mean (SD) N Mean (SD) P-value*
Injecting antibiotics 241 25.78 (16.63) 42 29.16 (18.35) 0.24
Oral medications 177 15.21 (9.34) 159 16.42 (14.26) 0.36
OPD assessment 28 12.70 (9.93) 24 9.1 (8.45) 0.08
Monitoring oxygen saturation 21 7.25 (10.94) 67 9.71 (10.97) 0.21
Ward round 49 4.78 (4.04) 48 5.37 (7.60) 0.36
Oxygen therapy 5 0.36 (0.95) 20 4.87 (8.45) 0.001
Discharge/paperwork 45 3.36 (2.23) 50 2.71 (3.03) 0.50
Monitoring vital signs 12 1.25 (3.48) 10 1.46 (2.22) 0.40
Intra-venous fluid 3 0.32 (1.06) 3 1.79 (6.09) 0.11
Diagnostic tests 3 0.42 (1.26) 5 0.75 (1.73) 0.22
Administering antimalarials 5 0.28 (1.01) 0 0 (0) 0.08
TOTAL 589 93.14 (37.99) 428 106.43 (54.76) 0.15
N total observations for each activity, OPD out-patient department
Injecting antibiotics: benzylpenicillin, chloramphenicol, ceftriaxone, gentamicin
Oral medications: paracetamol, cotrimoxazole, salbutamol, aminophylline
Antimalarials: artemisinin-based combination therapy, quinine. Diagnostic tests: malaria blood film, HIV antibody test
* T-test for a difference in mean time spent on activity between severe and very severe cases
Table 3 Human resources time and costs for severe and very severe pneumonia case management at Mchinji District Hospital
All Severe pneumonia Very severe pneumonia P-value
Mean time (SD), minutes
Senior clinical cadres 3.26 (8.22) 2.93 (7.94) 3.67 (8.68) 0.37
Clinical cadres 73.27 (34.76) 72.29 (37.68) 74.42 (31.76) 0.41
Support staff 11.44 (14.98) 7.28 (7.27) 16.29 (19.75) 0.01
HR costs, US$
Cost per child 30.99 29.52 32.69
Annual costs 24,947 14,817 9,906
One-way sensitivity analysis
Annual cost savings (range) 6,439
a (2,179–9,906)
b (−978–11,495)
a Based on PCV-13 vaccine efficacy estimates of 65 % (range: 22–100 %) against all-cause very severe pneumonia and 0 % against all-cause severe
pneumonia (McCollum ED, Nambiar, B, et al. Impact of the 13-valent pneumococcal conjugate vaccine on clinical and hypoxemic childhood pneumonia at the
community, health centre and hospital levels over three years in Malawi: a time series analysis of two districts, under review)
b Based on a +/− 25 % increase in the annual number of pneumonia inpatients under five years of age
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clerks worked significantly longer on children with very
severe pneumonia than on severe cases (P = 0.01).
Based on the average length of hospital stay for chil-
dren in the sample, nurses spent an average of 12 min
per bed-day on children with pneumonia (2 % of their
working hours), senior clinicians spent 5 min per bed-
day (1 %) and support staff spent 2 min per bed-day
(0.4 %). Senior clinical staff were in contact with the
patients mainly to prescribe and administer drug regi-
mens (38 % of average time spent per admission) and
during ward rounds (26 %), with the remaining time
dedicated to administrative activities. Nurses and clin-
ical technicians were also involved with administering
antibiotics and other drug regimens (58 % of average
time spent per admission) and most of the remaining
contact time with patients came during the OPD
assessment and admission (15 %) and monitoring of
oxygen saturation and vital signs (13 %). Support staff
were mostly involved in administering drugs (57 % of
average time spent per admission), assisting clinicians
with the paperwork (20 %) and during ward rounds
(14 %).
Costs of human resources
Mchinji District Hospital
In 2012, 303 children under 5 years of age with very
severe pneumonia and 502 with severe pneumonia were
admitted to Mchinji District Hospital. Using median sal-
aries for each cadre and the average exchange rate for
2012 (US$ 1 =MWK 248.59), the cost of salaries per
bed-day was US$ 2.02 for severe and US$ 2.20 for very
severe pneumonia cases. Table 3 shows costs per child
based on the average length of hospital stay in our sam-
ple. At an HR cost per child of US$ 31, Mchinji District
Hospital spent approximately US$ 24,947 on pneumonia
inpatients under the age of five in 2012. Based on
vaccine efficacy estimates of 65 %, the facility could save
around US$ 6,439 in staff salaries every year due to the
reduction in under-five pneumonia cases brought about
by the new vaccine.
National estimates
According to cMYP projections, 2,672,068 children
under the age of five lived in Malawi in 2012 [27]; and
the rate of pneumonia cases presenting at health facil-
ities in the same age group was 4,212/100,000 child
years [26]. This translates to annual HR costs of child-
hood pneumonia case management of US$ 3,487,875.
Reductions in incidence due to PCV-13 introduction
would free up an estimated US$ 2,057,846 (range: US$
1,709,059–US$ 2,406,634) every year, that the Malawian
Government currently spends on the ward staff caring
for pneumonia inpatients under the age of five.
Discussion
This study provides estimates of the time spent by ward
staff on all activities related to pneumonia case manage-
ment in children under five in a rural district hospital in
Malawi. Monetary valuations of the time are provided in
order to estimate the potential savings from reductions
in the number of pneumonia cases presenting at health
facilities after the introduction of PCV-13. According to
our estimates, at an average HR cost of around US$ 2
per bed-day, Mchinji District Hospital spends approxi-
mately US$ 24,947 every year in staff salaries alone.
About one third of this could be freed up for alternative
use if the projected reductions in the burden of childhood
pneumonia are realised. The estimated savings of over 2
million US$ at the national level would also be substantial,
considering that this constitutes roughly 0.8 % of total
health expenditure for Malawi in 2012 [28].
There are few comparable estimates of time and cost
of HR in the literature: this is the only known time use
study conducted in Malawi and among the first from a
low- or middle-income setting [6, 13, 14]. None of the
available results obtained using a similar method cov-
ered under-5 pneumonia case management. Existing
estimates of the HR costs of pneumonia treatment
from cost-effectiveness studies of PCV-13 introduction
used different methodologies with lower levels of
accuracy: of the three available economic evaluations of
PCV-13 from sub-Saharan Africa, two utilised treat-
ment cost estimates, including HR costs, from second-
ary data sources [11, 12], and one reported societal
cost estimates without differentiating between health
provider and patient costs, so that it is not possible to
identify the HR component [29]. Chola and Robberstad
reported provider costs of pneumonia of US$ 48 per
outpatient visit and US$ 215 per admission in Zambia,
although no breakdown of the individual cost compo-
nents, such as HR, is presented [10]. The costs of
childhood pneumonia were considerably higher than
those reported for under-five diarrhoea in the same
study, which were US$ 26 for outpatient visits and US$
78 per bed-day, respectively [10]. Only one study from
Fiji provided comprehensive provider cost estimates for
childhood pneumonia of US$ 19 per outpatient visit,
with personnel costs accounting for approximately
90 % of the cost [30]. However, this estimate cannot be
reliably compared to our results as it includes the costs
of pharmacy and overhead staff and a corresponding
estimate for inpatients is not reported.
Use of self-administered timesheets allowed us to ana-
lyse the differences in both the mix of activities and the
types of human resources involved in case management
between severe and very severe pneumonia cases. We
found that the excess contact time with very severe cases
was mostly provided by non-clinical support staff, such
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as hospital attendants, whose main tasks involved
administering drugs and assisting with paperwork. This
finding is of relevance empirically, as we show that the
difference in staff time allocation and cost between
severe and very severe pneumonia case management is
mostly driven by support staff in low-income settings. It
is also an important methodological finding, as this is
the first study to demonstrate that self-administered
timesheets can be used effectively among support staff
in these settings.
In terms of differences in treatment options, approxi-
mately one in 5 severe cases received antimalarials, while
they were not prescribed to any of the very severe cases.
This suggests that there may be some uncertainty in the
diagnosis when symptoms are not very severe and that
malaria is being treated as a ‘fail-safe’ diagnosis. An un-
intended consequence of vaccine introduction might
therefore be that the number of misdiagnosed cases of
malaria and the unnecessary prescription of antimalarials
may increase.
It should be noted that, while self-administered
timesheets had significant advantages in this context,
the study had some limitations. Firstly, the number of
tracked patients is relatively small and the study was
conducted at one single facility. While we have as-
sumed, in the absence of evidence to the contrary,
that the findings from this study population can be
generalised to the national level, this level of general-
isation should be treated with caution. In addition, at
the time this study was conducted, Mchinji District Hos-
pital did not have a functional x-ray unit, thus potentially
depriving clinical staff of an important tool for diagnosing
pneumonia. This is, however, a common occurrence in
resource-poor settings and we believe that our results are
informative and applicable to the majority of secondary
hospitals in Malawi and other countries in the region. An-
other limitation of the present study is that no reliable esti-
mates of herd immunity and of potential reductions in
incidence of adult pneumonia due to vaccination were
available. The estimated savings are therefore likely to be
underestimated and conservative. However, this effect
could be balanced out by the potential increase in inci-
dence due to serotype replacement and the appearance of
other pathogens. The vaccine effectiveness trial, moreover,
found a significant increase (58 %, range: 22–96 %) in
non-severe cases which, although less deadly, will result
in additional costs to health providers (McCollum ED,
Nambiar, B, et al. Impact of the 13-valent pneumococcal
conjugate vaccine on clinical and hypoxemic childhood
pneumonia at the community, health centre and hospital
levels over three years in Malawi: a time series analysis of
two districts, under review). These additional costs will be
particularly felt at the primary care level and by commu-
nity health workers following the revision of the WHO
Integrated Management of Childhood Illness guidelines,
which now recommend to treat some of the cases previ-
ously classified as severe pneumonia with oral amoxicillin
and home care [31]. We therefore believe that these esti-
mates of the HR costs of pneumonia treatment are the
most accurate available and a powerful tool for advocacy
in favor of mobilising funds in support of immunisation.
In terms of practical feasibility, self-administered time-
sheets monitored by internal observers were found to be
relatively inexpensive and effective for collecting time-
use data at Mchinji District Hospital. Key characteristics
of the study facility that made the technique suitable in
this context include the physical size of the children’s
ward, which occupies a single large room, and the rela-
tively small number of staff working on the ward (ap-
proximately 30 people at any one time). A single room is
easier to monitor and a smaller number of employees is
quicker and cheaper to train. In our experience, the use
of a data entry form structured like a logbook was easy
to handle by ward staff, who did not perceive data entry
to be unduly adding onto their daily workload. Since the
timesheets are comparatively more straightforward than
other data collection methods, the clinical staff on the
ward readily bought into the study and agreed to be
recruited as day-to-day supervisors, so that data quality
was ensured without having external observers on site
on a daily basis. However, since self-completion forms
rely heavily on the participation of facility staff in the
planning phase, we would not recommend this tech-
nique in larger facilities, where fluctuations in ward
personnel are usually higher, study preparation times
might be longer and inclusion of a larger number of
supervisory staff from other specialties, such as radiolo-
gists, might be necessary. In such a setting, where
increasing the number of facility staff and the amount of
their time on the study may be less feasible, it might be
best to hire external enumerators and supervisors and
carry out a standard time and motion study, thus likely
increasing overall costs.
Conclusions
This study makes innovative use of an established
method to estimate and value the time spent on case
management of childhood pneumonia in Malawi. Based
on the number of pneumonia inpatients admitted at the
study facility during 2012 and available vaccine efficacy
estimates, immunisation could result in over US$ 2
million annual cost savings on staff salaries alone. We
have demonstrated that self-administered timesheets can
be cheaply and successfully used in this setting to measure
the time spent by clinical and support staff on different ac-
tivities. These measures, in turn, can be used to generate
reliable estimates of the HR cost savings following PCV-13
introduction in Malawi.
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